POINT-Logo-Colour (blue).png
POINT Biopharma to Participate in Upcoming Investor Conferences
July 06, 2022 08:30 ET | POINT Biopharma
INDIANAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
ITM_Logo_Claim_RGB_high-res.png
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
June 21, 2022 11:45 ET | ITM Isotope Technologies Munich SE
First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June...
POINT-Logo-Colour (1).png
POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial
June 21, 2022 08:30 ET | POINT Biopharma
Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer...
POINT-Logo-Colour (1).png
POINT Biopharma to Participate in Upcoming Investor Conferences
May 19, 2022 17:30 ET | POINT Biopharma
INDIANAPOLIS, May 19, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (1).png
POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program
May 16, 2022 08:30 ET | POINT Biopharma
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy INDIANAPOLIS,...
POINT-Logo-Colour (1).png
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update
May 13, 2022 08:30 ET | POINT Biopharma
POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada...
POINT-Logo-Colour (1).png
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
May 05, 2022 09:15 ET | POINT Biopharma
INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT-Logo-Colour (1).png
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
April 26, 2022 08:30 ET | POINT Biopharma
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...
POINT-Logo-Colour (1).png
POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting
April 11, 2022 16:30 ET | POINT Biopharma
POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for...
POINT-Logo-Colour (1).png
POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update
March 25, 2022 08:30 ET | POINT Biopharma
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line data expected mid-2023 Phase 1 therapeutic trial for PNT6555, the...